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Identification of copy number variations (CNVs) through chromosomal microarray (CMA) testing is first 
line investigation in individuals with learning difficulties/congenital abnormalities. Although recognised that 
CMA testing may identify CNVs encompassing a cancer predisposition gene (CPG), limited information is 
available on the frequency and nature of such results.   
 
Methods 
We investigated CNV gains and losses affecting 39 CPGs in 3,366 pilot index case individuals undergoing 
CMA testing, and then studied an extended cohort (n=10,454) for CNV losses at 105 CPGs and CNV gains 
at 9 proto-oncogenes implicated in inherited cancer susceptibility. 
 
Results  
In the pilot cohort, 31/3,366 (0.92%) individuals had a CNV involving one or more of 16/39 CPGs. 30/31 
CNVs involved a tumour suppressor gene (TSG), and 1/30 a proto-oncogene (gain of MET). BMPR1A, 
TSC2 and TMEM127 were affected in multiple cases. In the second stage analysis, 49/10,454 (0.47%) 
individuals in the extended cohort had 50 CNVs involving 24/105 CPGs. 43/50 CNVs involved a TSG and 
7/50 a proto-oncogene (4 gains, 3 deletions). The most frequently involved genes, FLCN (n=10) and SDHA 
(n=7), map to the Smith-Magenis and cri-du-chat regions respectively.  
 
Conclusion 
Incidental identification of a CNV involving a CPG is not rare and poses challenges for future cancer risk 
estimation. Prospective data collection from CPG-CNV cohorts ascertained incidentally and through 
syndromic presentations is required to determine the risks posed by specific CNVs. In particular, 
ascertainment and investigation of adults with CPG-CNVs and adults with learning disability and cancer, 




The human genome contains marked structural variation and it is over 10 years since the first 
comprehensive copy number variant (CNV) map of the human genome was published (1). For children 
presenting with developmental delay/learning difficulties and/or congenital abnormalities, diagnostic 
germline chromosomal microarray (CMA) for causative CNVs is now a first line investigation and, together 
with advances in CMA technology leading to improving resolution (2), there are increasingly numbers of 
patients identified with CNVs of uncertain significance or for which the resulting phenotype is unclear. This 
is particularly pertinent where an identified CNV encompasses an inherited cancer (cancer predisposition 
gene/CPG) and there is no relevant personal or family history, a so-called incidental finding. 
With the mainstreaming of modern genomic investigations, CMA testing is often ordered by non-genetics 
health care professionals (e.g. paediatricians) who may have limited familiarity with familial cancer 
syndromes and are unable to advise on the full significance of the CMA result. Previously, Pichert et al (3) 
described the frequency of CNVs affecting 47 CPGs in 4,805 CMA analyses. We report an independent 






Participants and samples 
Samples were referred by paediatricians and clinical geneticists where constitutional diagnostic array 
comparative genomic hybridisation (aCGH) was requested to determine causes of developmental delay, 
learning difficulties, neurocognitive impairment and/or birth defects. Only arrays pertaining to the index 
case in a family were included. The following were excluded (i) patients with clinical features and/or a 
family history suggestive of the involvement of a known cancer predisposing gene (CPG) (ii) samples from 
prenatal diagnoses; and (iii) results involving whole chromosome or chromosome arm aneuploidy (iv) 
results where the CNV identified involving a CPG was present in mosaic form. Monozygotic twins were 
counted as one individual for the purposes of this study. A finding was considered positive where the 
involvement of a CPG was not suspected before testing (i.e. an incidental finding). CNVs included in the 
results were those where the CNV was considered to be causative of the index case’ presenting features, and 
also CNVs of either benign or uncertain significance.  Approval for the clinical audit study was provided by 
Birmingham Women’s NHS Foundation Trust and Central Manchester University Hospitals NHS 
Foundation Trust.  
Two cohorts of patients were analysed in two stages. Initially, a pilot cohort comprising 3,366 index case 
samples investigated between 1 Jan 2009 – 30 Sept 2013 at the West Midlands Regional Genetics 
Laboratory and then an extended cohort comprising 10,454 index case samples between 1 Jan 2011 and 31 
Dec 2015 at the Manchester Centre for Genomic Medicine. 
 
Gene Search Lists   
The pilot cohort (n=3,366) was analysed for CNV gains and losses involving a core set of 39 genes (4 
oncogenes, 35 tumour suppressor genes) associated with familial cancer predisposition syndromes (Table 
S1). In the 10k extended cohort (10,454 index patients), CNV losses were investigated in a panel of 105 
known CPGs (including the 39 genes analysed in the pilot cohort) comprising, 94 genes on the Illumina 
Trusight Cancer Panel (4) and 11 further candidate CPGs [CDKN1B, CDKN2B, ESR2, HIF2A, HOXB13, 
PDGFRA, POLD1, POLE, SMARCA4, SMARCE1, SDHA (5-15)]. 
Additionally, in the 10k extended cohort, CNV gains at nine of the105 genes [ALK, EGFR, HRAS, RHBDF2, 
CDK4, KIT, MET, PDGFRA, RET (10, 16-23)] were investigated as activating alterations have been 
described in hereditary cancer predisposition. Partial or whole gene losses and gains were noted and counted 
as positive findings.     
 
Laboratory methods and bioinformatics analysis 
Testing was undertaken in CPA accredited laboratories. aCGH analysis was carried out using DNA 
extracted from peripheral blood or mouthwash samples using standard techniques.  
For the pilot cohort, aCGH was carried out using either the BlueGnome CytoChip 1Mb BAC (Bacterial 
Artificial Chromosome) array or the Bluegnome 8x60k v2.0 (ISCA) design oligonucleotide array. aCGH 
data analysis was performed using  BlueFuse Multi software. Copy number variant (CNV) detection using 
the Bluegnome 1Mb BAC array was carried out with a successful BAC inclusion threshold of >95%. Single 
clones were called as copy number variants using Log2 thresholds of +/-0.3. Copy number variant (CNV) 
detection using the Bluegnome 8x60k v2.0 (ISCA) design oligonucleotide array was carried out with a 
minimum 3 probe inclusion using Log2 ratio thresholds of +/-0.3. No minimum size threshold was applied 
for either platform. 
For the 10k extended cohort, aCGH testing was carried out using Oxford Gene Technology (OGT) 
CytoSureTM ISCA v2 (8x60k) arrays for all cases with the exception of P102 which was tested using OGT 
CytoSureTM Constitutional v3 Array (8x60k). aCGH data analysis was performed using OGT CytoSureTM 
Interpret software. Copy number variant (CNV) detection was based on a minimum 4 probe inclusion using 
Log2 thresholds of ≥ 0.35 for gains and ≤ -0.6 for losses, and no minimum size threshold applied. 
For both studies, automatically called CNVs were subject to manual assessment to exclude artefacts and a 
manual screen for mosaic aberrations was also performed. Inheritance studies were performed using 
karyotype analysis, targeted aCGH or in situ hybridisation studies, as appropriate where parental samples 
were available. 
CNV co-ordinates described are based on the minimum affected region as per standard practice and all co-
ordinates are GRCh37/hg19 except where otherwise stated. 
 
Statistical Analysis 
Data are displayed as mean ± SD. Continuous data were analysed using a two-tailed Student’s t-test. A P-





Stage 1: Pilot Cohort Analysis 
Within the 3,366 index patients there were 31 individuals (15 males, 16 females) harbouring 31 CNVs 
involving one or more of the 39 CPGs analysed (Table S2). The ‘incidental finding’ rate was 0.92% 
(31/3366). Mean age at CNV analysis in individuals with a positive finding was 51.9 months (SEM 14.2, 
range 0-312 months, median 8 months).  In 16/31 cases the CPG-related CNV was considered to be relevant 
to the clinical phenotype and in 15 individuals the CNV identified was considered to be either unrelated or 
of uncertain clinical significance. In 10 cases the CNV encompassing the cancer gene was de novo and in 14 
cases the CNV was inherited (including one where the child inherited the unbalanced form of a parental 
balanced translocation). The family history was known in 11 of the 14 cases where the CNV was inherited 
(excluding the case with the unbalanced form of the parental translocation), and there were no clinical 
features in keeping with a germline pathogenic alteration of the CPG.   
Only one of the CNVs involved an oncogene, a gain encompassing MET. The remaining 30 CNVs (20 gains 
and 10 losses) involved a tumour suppressor gene and two CNVs affected multiple CPGs: a gain involving 
MSH2 and MSH6; and a deletion encompassing BMPR1A and PTEN thought likely causative of the learning 
difficulties phenotype. In six cases the CNV arose as consequence of a complex chromosomal 
rearrangement and, in all six, resulted in the gain of a tumour suppressor gene (TSC2 x3, PMS2 x1, VHL x2). 
The 31 “incidental findings” CNVs involved 16/39 (41.0%) CPGs in the pilot stage gene list with BMPR1A 
(in 6 cases), TSC2 (n=4) and TMEM127 (n=3) affected in multiple cases (Fig. 1).  
 
Stage 2: Extended Cohort Analysis  
49 (17 females, 32 males) of 10,454 individuals (0.47%) had a total of 50 CNVs involving one or more 
CPGs on the Stage 2 gene list (see Table S1 and Table S3. The mean age at aCGH in individuals with a 
positive finding was 87.5 months (SEM 15.0, range 0-460 months, median 46.5 months).  In 40 of the 
individuals the array finding involving the cancer gene was thought to be causative of the clinical phenotype 
in the index individual and in 9 cases the CNV identified was of uncertain clinical significance or unrelated 
to the presenting features.  In 27 cases the CNV arose de novo and in 6 cases the CNV was inherited. In 3 of 
these 6 cases the child had inherited the unbalanced form of a parental balanced translocation. In the 
remaining 3 cases, the family history was known in 2 cases and there were no clinical features in keeping 
with a germline pathogenic alteration of the CPG.   
7 of the 50 CNVs involved an oncogene: 4 gains (HRAS x2, MET and PDGFRA) and 3 deletions (METx2, 
one involving both KIT/PDGFRA).  The remaining 43 CNVs were deletions involving TSGs. In one case 
there was a heterozygous contiguous deletion of two TSGs (BLM and FANCI).  Four of the CNVs (in three 
individuals) arose as a consequence of complex chromosomal rearrangement resulting in gain of an 
oncogene in three cases (HRAS x2, MET x1) and loss of a tumour suppressor gene (SDHA) in one. These 50 
CNVs affected 24 of the 105 genes on the search list (24/105 = 22.9%) with CNVs affecting FLCN 
accounting for 10/50 (20%) and of SDHA 7/50 (14%) (Fig. 2).  
 
Joint Analysis of Stage 1 and Stage 2 data sets and CPG lists  
Oncogene gains: 3 of 13,820 cases (0.02%) in the combined Stage 1 and Stage 2 cohorts had a CNV gain at 
one or more of the 4 oncogenes (RET, PDGFRA, MET and KIT) in the Stage 1 gene list with CNV gains 
occurring twice at the MET locus (including one individual with a complex rearrangement leading to gain) 
and once at the PDGFRA locus. Three individuals had a deletion of one or more of these oncogenes 
(including the one individual with the deletion of both MET and PDGFRA and two with a deletion of MET) 
(Table S4). 
TSG losses: 30 of 13,820 (0.22%) individuals in the combined Stage 1 and 2 cohorts had a partial or whole 
deletion involving one or more of 35 tumour suppressor genes (Table S4).  In 22/30 cases the CNV 
identified was thought to be causative of the child’s presenting features and was thought to be either 
unrelated to, or of uncertain significance, in the remaining eight.  In 17 cases the CNV identified was de 
novo and was found to be inherited in 6 individuals (including one where the child had inherited the 
unbalanced form of the parental balanced translocation). 15 of the 39 (38.5%) genes on the common search 
list (12 tumour suppressor genes and 3 oncogenes) were affected by a deletion CNV with SDHA being 
involved in 9 CNVs and BMPR1A in 6 (Fig. 3) (Table S4).  
 
CNVs encompassing CPGs residing within the known chromosomal microdeletion regions: 17p11.2 and 
5p15.22   
10 individuals (Stage 2 cohort) had a CNV encompassing FLCN (chr17:17,115,527-17,140,502) which 
resides within the Smith-Magenis Syndrome (SMS) region on 17p11.2 (Decipher chr17: 16,773,072 – 
20,222,149) (24), accounting for 20% of the total CNVs identified (Fig. 2, Fig. 4). Five of the CNVs were 
known to be de novo and in five the inheritance was unknown.  In four individuals (P113, P111, P116, 
P119) the majority of the CNV overlapped with but did not encompass the SMS region. In the remaining six, 
the SMS region was contained within the CNV.  
Nine individuals (two from Stage 1 and seven from Stage 2) had a deletion encompassing SDHA 
(chr5:218,356-256,814) which resides toward the 5’ end of the cri-du-chat Region (Decipher chr5:10,001 – 
12,533,304) (24) accounting for 26.0% of the total number of CNVs identified in the combined cohorts (Fig. 
3, Fig. 5). In five individuals the CNV was within the cri-du-chat region and, in the remaining four, the 
CNV identified extended 3’ beyond the critical region (Fig. 5). The CNV was inherited in three individuals 
(including the individual with the unbalanced translocation leading to loss of SDHA and gain of HRAS), de 















CMA testing is now routinely ordered for individuals presenting with undiagnosed learning difficulties 
and/or developmental abnormalities and is often undertaken outwith the genetics clinic, for example in the 
paediatric mainstream setting.  
Whilst these investigations provide the opportunity for diagnosis, the CNVs identified may encompass or 
involve genes where intragenic alteration or whole gene copy number losses are known to be associated 
with predisposition to other condition(s) unrelated to the presenting features and can be classed as incidental 
findings. Unlike other genome wide molecular genetic diagnostic strategies, such as whole exome and 
genome sequencing for which results can be filtered in a gene specific manner, identified CNVs are usually 
visible to the investigator.  Incidental finding CNVs involving CPGs can present significant counselling 
challenges as (i) whilst the phenotype and cancer risks of intragenic mutations in a CPG may be well 
defined the risks associated with large CNVs are often unclear as deletion of additional in cis genes might 
modify cancer risks (25); (ii) the known cancer risks associated with CPGs are for individuals ascertained 
because of a family history and are likely to be lower for population-based ascertainment; and (iii) most 
CNVs involved CPGs associated with later onset cancers whereas CMA is more commonly performed in a 
paediatric setting (mean age at positive finding in our pilot and extended cohorts was 51.9m and 87.5m 
respectively). Nevertheless CPG-CNVs cannot be ignored - as exemplified by two infants (P136 and P137, 
ages at aCGH 0m and 3m respectively) with deletions of ~50Mb and 24.5Mb respectively encompassing 
RB1 who subsequently developed clinical retinoblastoma after the CMA was requested. Whilst 
retinoblastoma is highly penetrant at a young age (mean age diagnosis of bilateral retinoblastoma 15m) (26), 
and the tumour penetrance for intragenic mutation of other CPGs is often more variable, this highlights that 
CNVs encompassing a CPG may be of clinical consequence and should be considered as a paradigm for the 
need to report such findings until more is known regarding their effects.  
Indeed recent analysis of a range of CPGs showed that large deletions including whole gene deletions were 
associated with fairly typical cancer predisposition compared to point mutations (27). Deletions of CPGs 
with substantial childhood onset risks such as SMARCB1 (malignant rhabdoid tumour) and TP53 (brain and 
sarcoma) also appear to be not infrequent and there is no evidence these deletions are less penetrant than 
point mutations (27).  On the other hand, we also detected an inherited deletion encompassing BMPR1A 
(P005) where there was no family history of polyposis. Whilst BMPR1A mutations are of lower penetrance 
than RB1 (28), it likely that other factors influencing penetrance/expression are also involved. Varying 
phenotypic consequences of large deletions encompassing disease-causing genes are a recognised challenge 
(29) and the mechanisms underlying such variable phenotypic effects may include combinations of 
underlying genomic architecture, long range regulatory effects and, more recently recognised, the influence 
of topology associated domains (30).  In addition, for CNVs involving TSGs the somatic “second hit” might 
result in homozygous loss of many genes in the cancer cell and result in non-viability through loss of an 
essential gene or by producing, in combination with loss of the CPG, a synthetic lethal state (31).  
In four individuals we identified partial deletions of a TSG. Whilst with CMA it is not possible to precisely 
characterise the breakpoints, we would expect multi-exon deletions to be pathogenic, particularly where they 
have been described in the corresponding familial cancer syndrome (32-35). However, in these partial 
deletion cases we cannot exclude the possibility of expression of an abnormally truncated gene product, 
although one patient, (P029), did subsequently develop features of tuberous sclerosis indicating 
pathogenicity.  
For CNVs resulting in the gain of a TSG or proto-oncogene, the phenotypic consequences can also be very 
difficult to interpret. CMA gives no positional information (other than where there is also a cytogenetically 
characterised complex rearrangement, as occurred in 8 individuals) and a CMA-detected copy number gain 
might be caused by an intragenic duplication that inactivated a TSG or gain of a functional proto-oncogene – 
either of which might be associated with a cancer risk.  
The CPGs most commonly involved in CNVs were SDHA and FLCN and both reside within the 
chromosomal micro-deletion regions for cri-du-chat (Decipher chr5:10,001–12,533,304) and Smith-Magenis  
(Decipher chr17: 16,773,072 – 20,222,149) respectively (24, 36-37). Although toward the 5’ end, SDHA is 
within the cri-du-chat deleted region which has an incidence of 1:15,000 – 1:50,000 (38). Intragenic SDHA 
inactivating mutations may be associated with phaeochromocytoma, paraganglioma and gastrointestinal 
stromal tumours (GIST) (15, 39). Though the penetrance of familial SDHA mutations has been estimated at 
~40% by age 40 years (40), other evidence suggests that the penetrance is much lower (39) and to date we 
are not aware of any SDHA-related tumours reported in patients with cri-du-chat (41). Nevertheless, subject 
to appropriate ethical considerations, it would be of interest to investigate adults with cri-du-chat deletions 
involving SDHA for subclinical evidence of SDHA-related tumours. 
FLCN lies within the Smith-Magenis syndrome (SMS) region, on 17p11.2 and accounted for 20% of the 
CNVs identified. Germline mutations in FLCN cause Birt-Hogg-Dube (BHD) syndrome which is 
characterised by the apprearance of fibrofolliculomas from the third decade and renal cell carcinoma in 
about 25-30% of cases (42). RCC has been described in patients with SMS (43) but the precise risk of RCC 
in SMS patients with FLCN loss is unclear and further information is required to determine whether 
surveillance for RCC should be offered routinely. Nevertheless, in the presence of lung cysts or 
fibrofolliculomas (which on average precede RCC in BHD syndrome) it would seem prudent to do so. 
Our CNV detection rate encompassing a CPG was between 0.3% (Stage 1 and 2 combined, n=13,820) and 
1% (Stage 1 pilot, n=3,366) in individuals undergoing diagnostic CMA. Pichert et al (2011) found CNVs 
affecting CPGs in 0.6% of 4805 diagnostic arrays and Boone et al (44) detected 0.9% in 9,005 arrays 
although this study involved a search list of 40 genes involved in adult onset disorders not specifically 
focussed toward cancer genes. 
This study is the largest to date of CNVs affecting CPGs detected as incidental findings has demonstrated 
that optimal management of incidentally detected CPG-CNVs and will require systematic collection of long-
term follow up data and international data sharing. In particular detailed studies of the clinical significance 
of SDHA and FLCN loss in patients with cri-du-chat and SMS would address the most frequently detected 
CPG-CNVs. Though CMAs are routinely performed in children with learning disability, significant numbers 
of adults with learning disability are likely not to have had high resolution CMA testing and routine 
reinvestigation of such patients could provide important information on cancer risks. In addition, we are 
compiling a database of adults with pathogenic CNVs and cancer and request that appropriate cases should 
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Figure Legends 
 
Figure 1. Percentage of CNVs detected in the Stage 1 pilot cohort affecting the CPG shown and whether the 
CNVs detected were gains or deletions. Where a CPG gene present in Table S1 is not shown then no CNV 
involving it was detected. 
 
Figure 2.  Percentage of CNVs detected in the Stage 2 extended cohort affecting the CPGs shown and 
whether the CNVs detected were gains or deletions. Where a CPG is not shown then no CNV affecting it 
was detected. 
 
Figure 3.  Percentage of deletion CNVs detected in the combined Stage 1 pilot and Stage 2 extended cohorts 
affecting the CPGs shown. Where a CPG is not shown then no deletion CNV affecting it was detected. 
 
Figure 4. Schematic diagram of the 10 CNVs encompassing FLCN relative to the mid-point of FLCN. Each 
bar represents the CNV identified in the patient shown. The central axis represents the mid-point of FLCN, 
and the distance in base-pairs from this mid-point is shown on the horizontal X-axis. 
 
Figure 5. Schematic diagram of the 9 CNVs encompassing SDHA relative to the mid-point of SDHA. Each 
bar represents the CNV identified in the patient shown. The central axis represents the mid-point of SDHA, 







Table S1.  Cancer Predisposing Genes (CPGs). 
 
 
CPG  CPG in Pilot 
Cohort 











Bi-allelic or Mono-allelic 
(with respect to cancer 
predisposion) 
 








No Yes 605555 11q13.3 Monoallelic 
 
 
Pituitary adenoma predisposition 
 
600634 / 102200 
ALK* No Yes 105590 2p23.2-23.1 Monoallelic  
 


















Monoallelic Breast cancer susceptibility 
 
114480 





No Yes 603089 3p21.1 Monoallelic Tumour Predisposition Syndrome 614327 
BLM 
 
No Yes 604610 11q26.1 
 





Colorectal cancer susceptibility 114500 
BMPR1A 
 










































Breast cancer susceptibility 114480 















































No Yes 600778 12p13.1 Monoallelic 
 





No Yes 600856 11p15.4 
 






Yes Yes 600160 9p21.3 
 
Monoallelic Melanoma susceptibility 
 
606719 / 155755 / 
155601 
 
CDKN2B No Yes 600431 9p21.3 Monoallelic 
 




No Yes 116897 19q13.11 Monoallelic 
 










No Yes 604373 22q12.1 Monoallelic Breast cancer susceptibility 114480 
CYLD 
 




Monoallelic Familial cylindromatosis 
 





















Monoallelic Familial pleuropulmonary blastoma tumour 
predisposition syndrome 
 
601200 / 138800 / 




No Yes 614184 2q37.1 Biallelic Perlman syndrome 267000 
EGFR* 
 
No Yes 131550 7p11.2 Monoallelic  Non small cell lung cancer susceptibility  211980 
EPCAM 
 
No Yes 185535 2p21 
 














No Yes 133510 2q14.3 
 









Biallelic Xeroderma pigmentosum (F) 278760 
ERCC4 
 




Biallelic Fanconi Anaemia (Q) 615272 
ERCC5 
 




Biallelic Xeroderma pigmentosum (G) 278780 





No Yes 608177 8q24.11 
 










Monoallelic Multiple Exostoses, type 2 133701 
EZH2 
 
No Yes 6011573 7q36.1 
 


















































No Yes 613897 11p14.3 
 




No Yes 602956 9p13.3 
 








Biallelic Fanconi anaemia (I) 609053 
FANCL 
 
No Yes 608111 2p16.1 
 
Biallelic Fanconi anaemia (L) 614083 
FANCM 
 




Biallelic Fanconi anaemia? PS227650 
FH 
 














No Yes 607273 17p11.2 
 






No Yes 137295 3q21.3 Monoallelic Acute myeloid leukemia susceptibility 
 







No Yes 300037 Xq26.2 
 








No Yes 603349 2p21 Monoallelic 
 
Paraganglioma susceptibility PS168000 
HNF1A 
 



















No Yes 190020 11p15.5 Monoallelic  Costello Syndrome 218040 
















































Lynch Syndrome PS120435 
 
Biallelic Congenital mismatch repair deficiency 276300 
MSH2 
 






Lynch Syndrome PS120435 
Biallelic Congenital mismatch repair deficiency 276300 
MSH6 
 






Lynch Syndrome PS120435 
Biallelic Congenital mismatch repair deficiency 
 
276300 
MUTYH Yes Yes 604933 1p34.1 Biallelic MUTYH associated polyposis 608456 
NBN 
 
No Yes 602667 8q21.3 
 































No Yes 606681 5q35.3 Monoallelic 
 
Sotos Syndrome 117550 
PALB2 
 
No Yes 610355 16p12.2 
 
Mononallelic  Breast cancer susceptibility 
 
114480 
















No Yes 603851 4p13 Monoallelic Neuroblastoma susceptibility 613013 
PMS1 
 
No Yes 600258 2q32.2  Monoallelic  Lynch Syndrome  PS120435 
PMS2 Yes Yes #614337 7p22.1 Monoallelic Lynch Syndrome PS120435 
    
Biallelic Congenital mismatch repair deficiency 276300 
POLD1 
 




























Yes Yes 601309 9q22.32 
 





Yes Yes 601728 10q23.31 
 









Ovarian cancer susceptibility  
 
16700 





No Yes 602954 17q12 Mono-allelic  
 






























Monoallelic  Multiple endocrine neoplasia, Familial 
medullary thyroid cancer 
171400 / 162300 / 
155240 
 





No Yes 151385 21q22.12 Monoallelic Acute myeloid leukaemia, Familial platelet 
disorder with associated myeloid 
malignancy  
 
601626 / 601399 
SBDS No Yes 607444 7q11.21 Biallelic Schwachman-Diamond Syndrome 260400 
    
SDHAF2 
 

































































No Yes 603254 19p13.2 Monoallelic Rhabdoid tumour predisposition syndrome-
2 








































Monoallelic Familial medulloblastoma  























Yes Yes #191100 9q34.13 
 
Monoallelic Tuberous sclerosis PS191100 
TSC2 
 
Yes Yes 191092 16p13.3 
 
Monoallelic Tuberous sclerosis PS191100 
VHL
#
 Yes Yes 608537 3p25.3 Monoallelic Von Hippel Lindau Syndrome 
 
193300 






Yes Yes 607102 11p13 Monoallelic WAGR 




194072 / 194070 / 
194080 / 136680 
XPA No Yes 611153 
 
 









, paternal transmission of mutant allele associated with tumour risk; *, gain of function; 
#
, heterozygous deletion mutant allele associated with 





Table	  S2.	  CNVs	  detected	  involving	  a	  CPG	  in	  the	  Stage	  1	  Pilot	  Cohort	  Analysis.	  	  
Patient  CPG Del / gain 
of CPG  
Co-ordinates of 
CNV affecting CPG 







or inh   
Other array / 
cytogenetic 
findings 










array (m)  
Sex 
F/M 




unrelated	   inh	   Nil	   N/A	   No	  relevant	  FHx	   31	   F	  




pathogenic	   unknown	   Nil	   N/A	   Nil	   60	   M	  




pathogenic	   dn	   Nil	   N/A	   Nil	   13	   M	  




pathogenic	   dn	   Nil	   N/A	   Nil	   1	   M	  




pathogenic	   inh	   Nil	   N/A	   No	  relevant	  FHx	   0	   M	  
P006	   BMPR1A	  &	  
PTEN	  




pathogenic	   dn	   Nil	   N/A	   Nil	   0	   F	  




unrelated	   inh	   Nil	   N/A	   No	  relevant	  FHx	   0	   F	  
P008	   MSH2	  &	  
MSH6	  
gain	   arr[NCBI36]	  
2p22.2p16.2(37,472,079-­‐
54,403,333)x3	  	  







on	  chr2	  from	  a	  
carrier	  parent	  
	  
312	   F	  
P009	   NF1	   gain	   arr[NCBI36]	  
17q11.2(25,997,842-­‐
27,385,919.5)x3	  	  
unrelated	   inh	   Nil	   N/A	   No	  relevant	  FHx	  	   0	   M	  
	  
P010	   PMS2	   gain#	  	   arr[GRCh37]	  
7p22.3p21.3(54,215-­‐
7,690,132)x3	  
pathogenic	   unknown	   46,XY,der(22)t(7;22)(p21.3
;p11)	  
pathogenic	   Likely	  child	  
inherited	  
unbalanced	  






50	   M	  




pathogenic	   unknown	   Nil	   N/A	   Nil	   55	   F	  
P012	   PTEN	   gain	   arr[GRCh37]	  
10q23.31(89,635,555-­‐
89,665,005)x3	  
unrelated	   inh	   arr[GRCh37]	  
15q13.2q13.3(30,491,443-­‐
32,509,897)x3	  
unrelated	   No	  relevant	  FHx.	  




Partial	  gain	  of	  
PTEN.	  
	  
1	   F	  




inh	   Nil	   N/A	   No	  relevant	  FHx.	  
Analysis	  by	  BAC	  
array	  
	  
180	   M	  




pathogenic	   inh	   Nil	   N/A	   No	  relevant	  FHx	   192	   F	  




pathogenic	   dn	   Nil	   N/A	   Nil	   8	   F	  















one	  parent	  and	  
a	  balanced	  
translocation	  
from	  the	  other	  
parent.	  	  
	  
2	   M	  
P017	   SDHD	   gain	   arr[GRCh37]	  
11q23.1(111,883,595-­‐
112,272,219)x3	  
unrelated	   inh	   arr[GRCh37]	  
2p13.1p12(74,433,160-­‐
75,699,530)x3	  





one	  parent	  (no	  
FISH	  
undertaken).	  
175	   F	  
	  






unknown	   Nil	   N/A	   FHx	  unknown	  	   8	   F	  




unrelated	   unknown	   Nil	   N/A	   FHx	  unknown	  	   0	   M	  
P020	   SMARCB1	   gain	   arr[GRCh37]	  
22q11.23(23,822,957-­‐




unknown	   Nil	   N/A	   No	  relevant	  FHx	   124	   F	  




unrelated	   inh	   Nil	   N/A	   No	  relevant	  FHx	   1	   F	  






unknown	   Nil	   N/A	   Nil	   35	   M	  




unrelated	   inh	   Nil	   N/A	   No	  relevant	  FHx	   6	   M	  


















5	   F	  




unrelated	   inh	   Nil	   N/A	   No	  relevant	  FHx.	  
Partial	  gain	  of	  
TP53.	  
179	   M	  
P026	   TSC2	   gain#	  	   arr[NCBI36]	  
16p13.3p13.13(12,798-­‐
10,656,496)x3	  	  
pathogenic	   inh	   46,XY.ish	  
der(10)t(10;16)(q26.2;p13.
13)(10ptel-­‐,16ptel+)	  







0	   F	  
P027	   TSC2	   gain#	  	   arr[NCBI36]	  
16p13.3p12.3(12,798-­‐
17,285,210)x3	  
pathogenic	   dn	   46,XX,der(1)t(1;16)(q44;p1
2.3)dn	  
pathogenic	   Nil	   9	   F	  
P028	   TSC2	   gain#	  	   arr[GRCh37]	  
16p13.3(93,748-­‐
3,702,950)x3	  
pathogenic	   dn	   46,XY,der(3)t(3;7)(p26.1;p
21)dn,	  
der(7)t(7;16)(p21;p16.3)dn





pathogenic	   Nil	   50	   M	  
P029	   TSC2	   del	   arr[GRCh37]	  
16p13.3(2,097,019-­‐
2,099,039)x1dn	  








1-­‐2	  and	  part	  of	  








exon	  3	  and	  5'	  
UTR	  to	  exon	  3	  
been	  described	  
in	  TS	  (32-­‐33).	  
7	   M	  
P030	   VHL	   gain#	  	   arr[GRCh37]	  
3p26.1p24.2(7,543,632-­‐
24,901,101)x3	  





pathogenic	   Nil	   104	   M	  
P031	   VHL	   gain#	  	   3p26.1	  to	  3p24.3	  (RP11-­‐
277D17-­‐>RP11-­‐208G16)x3	  
pathogenic	   dn	   46,XX,der(3)t(3;6)(p26.1;q
25.2)dup(3)(p26.1p24.3)dn





pathogenic	   Nil	   0	   F	  
del,	  deletion;	  FHx,	  family	  history;	  dn,	  de	  novo;	  inh,	  inherited;	  *	  oncogene;	  #	  presence	  of	  a	  complex	  chromosomal	  rearrangement;	  F,	  female;	  M,	  male	  
	  	  
Table	  S3.	  CNVs	  detected	  involving	  a	  CPG	  in	  the	  Stage	  2	  Extended	  Cohort	  Analysis.	  	  





affecting CPG  









Other array / 
cytogenetic findings 
Other array / 
cytogenetic 
findings: benign / 
pathological / 
unrelated 
additional notes age at array (m) Sex F/M 




pathogenic	   dn	   t(5;8)(q15;q13)	  dn	   N/A	   nil	   205	   female	  
P102	   BLM	  &	  
FANCI	  




pathogenic	   unknown	   nil	   N/A	   nil	   12	   male	  




unrelated	   inh	   	  t(1;10)(p32;q23.2)	  inh	   unrelated	   No	  FHx	  relevant	  to	  
cancer	  gene.	  Deletion	  








deletions	  of	  exons	  1-­‐3	  
and	  2-­‐11	  been	  described	  
(34-­‐35).	  
26	   male	  




pathogenic	   dn	   nil	   N/A	   nil	   175	   male	  




pathogenic	   unknown	   nil	   N/A	   nil	   102	   male	  






inh	   nil	   N/A	   No	  FHx	  relevant	  to	  
cancer	  gene	  
177	   male	  











both	  uncertain	  significance	   one	  additional	  CNV	  
inherited	  from	  each	  
parent	  
195	   female	  




pathogenic	   dn	   nil	   N/A	   nil	   2	   male	  




pathogenic	   dn	   nil	   N/A	   nil	   47	   male	  




pathogenic	   dn	   nil	   N/A	   nil	   1	   male	  




pathogenic	   dn	   nil	   N/A	   nil	   12	   female	  




pathogenic	   unknown	   nil	   N/A	   nil	   33	   male	  




pathogenic	   dn	   nil	   N/A	   nil	   40	   female	  




pathogenic	   dn	   nil	   N/A	   nil	   45	   male	  




pathogenic	   unknown	   nil	   N/A	   nil	   63	   female	  




pathogenic	   unknown	   nil	   N/A	   nil	   95	   male	  




pathogenic	   dn	   nil	   N/A	   nil	   106	   male	  




pathogenic	   unknown	   nil	   N/A	   nil	   136	   female	  




pathogenic	   unknown	   nil	   N/A	   nil	   444	   female	  
P121	   HRAS*	   gain#	   arr[GRCh37]	  
11p15.5p15.2(113,08
2-­‐14,430,533)x3.	  	  






pathogenic	   Child	  has	  inherited	  from	  
each	  parent	  (i)	  





associated	  with	  learning	  
difficulties.	  	  Same	  
0	   female	  
individual	  as	  below.	  
	  
P121	   SDHA	   deletion#	   arr[GRCh37]	  
5p15.33p15.31(22,14
9-­‐9,700,223)x1	  






pathogenic	   Child	  has	  inherited	  from	  
each	  parent	  (i)	  





associated	  with	  learning	  
difficulties.	  	  Same	  
individual	  as	  above.	  
	  
0	   female	  
P122	   HRAS*	   gain#	   arr[GRCh37]	  
11p15.5(113,082-­‐
2,550,805)x3	  
pathogenic	   inh	   arr[GRCh37]	  
2q37.3(237,463,855-­‐
243,087,748)x1	  
pathogenic	   Child	  has	  inherited	  




6	   female	  
P123	   KIT*	  and	  
PDGFRA*	  




pathogenic	   dn	   nil	   N/A	   nil	   292	   female	  





dn	   nil	   N/A	   Not	  known	  if	  deletion	  on	  
pat	  or	  mat	  chr.	  	  
	  
100	   male	  




pathogenic	   dn	   nil	   N/A	   nil	   162	   female	  





pathogenic	   dn	   nil	   N/A	   nil	   272	   female	  
P127	   MET*	   gain#	  	  	  	   arr[GRCh37]	  
7q21.3q36.3(94,257,
592-­‐159,124,141)x3	  	  
pathogenic	   dn	   46,X,der(X)t(X;7)(p21.3;q21.3
).	  arr[GRCh37]	  	  
Xp22.33p21.3(310,953-­‐
28,515,804)x1	  	  	  
	  
pathogenic	   nil	   29	   female	  




pathogenic	   dn	   nil	   N/A	   nil	   0	   male	  









unknown	   nil	   N/A	   Maximum	  region	  of	  CNV	  
contains	  all	  of	  exons	  1-­‐6	  
and	  part	  of	  exon	  7	  of	  
transcript	  NM_006206.4	  
of	  PDGFRα	  
33	   male	  
P130	   PMS1	   deletion	   arr[GRCh36]	  
2q32.2q33.1(189,294
,117-­‐200,158,719)x1	  
pathogenic	   dn	   nil	   N/A	   nil	   57	   male	  




pathogenic	   dn	   nil	   N/A	   nil	   6	   male	  




pathogenic	   dn	   nil	   N/A	   nil	   30	   male	  






unknown	   nil	   N/A	   nil	   80	   male	  




pathogenic	   unknown	   nil	   N/A	   nil	   46	   male	  






unknown	   arr[GRCh37]	  2p21(	  
44,518,437-­‐44,542,918)x3	  
uncertain	  significance	   Deletion	  exons	  1-­‐25	  POLE	  
on	  minimum	  co-­‐
ordinates.	  Maximum	  co-­‐




122	   male	  




pathogenic	   dn	   nil	   N/A	   subsequently	  developed	  
RB	  
0	   female	  





pathogenic	   dn	   nil	   N/A	   subsequently	  developed	  
RB	  as	  did	  MZ	  twin	  
3	   male	  





pathogenic	   dn	   arr[GRCh36]	  
5q33.2(155,149,896-­‐
155,496,459)x3	  
inh.	  uncertain	  signficance	  	   child	  previously	  noted	  to	  
have	  unexplained	  low	  
platelet	  count	  
137	   male	  




pathogenic	   unknown	   nil	   N/A	   nil	   0	   male	  




pathogenic	   unknown	   arr[GRCh37]	  
5p15.1p14.1(18,215,614-­‐
26,972,861)x3	  	  
uncertain	  significance	   nil	   3	   female	  




pathogenic	   dn	   nil	   N/A	   nil	   6	   female	  






inh	   nil	   N/A	   nil	   16	   male	  




pathogenic	   dn	   nil	   N/A	   nil	   26	   male	  




pathogenic	   unknown	   nil	   N/A	   nil	   460	   male	  





pathogenic	   dn	   nil	   N/A	   nil	   74	   male	  





pathogenic	   dn	   nil	   N/A	   del	  on	  pat	  chr	   13	   female	  









unknown	   nil	   N/A	   Maximum	  region	  of	  CNV	  
deletes	  exons	  1-­‐14	  of	  
SMARCA4.	  Minimum	  
region	  not	  involve	  
SMARCA4.	  
50	   male	  





pathogenic	   unknown	   nil	   N/A	   nil	   148	   male	  




pathogenic	   dn	   nil	   N/A	   nil	   97	   male	  






unknown	   nil	   N/A	   nil	   191	   male	  
del,	  deletion;	  FHx,	  family	  history;	  dn,	  de	  novo;	  inh,	  inherited;	  *	  oncogene;	  #	  presence	  of	  a	  complex	  chromosomal	  rearrangement;	  F,	  female;	  M,	  male	  
	  
Table	  S4.	  CNVs	  detected	  involving	  a	  CPG	  in	  both	  the	  Stage	  1	  and	  Stage	  2	  Cohort	  Analyses.	  	  
Patient  CPG Del / 
gain of 









CNV dn or inh   Other array / 
cytogenetic 
findings 
Other array / cytogenetic 
findings: benign / 












Pathogenic	   dn	   t(5;8)(q15;q13)	  dn	   N/A	   Nil	   205	   F	  




Unrelated	   inh	   	  t(1;10)(p32;q23.2)	  inh	   unrelated	   No	  FHx	  relevant	  to	  
cancer	  gene.	  












deletions	  of	  exons	  
1-­‐3	  and	  2-­‐11	  have	  
been	  described	  (34-­‐
35)	  	  
26	   M	  




Pathogenic	   dn	   nil	   N/A	   Nil	   175	   M	  




Pathogenic	   dn	   Nil	   N/A	   Nil	   13	   M	  




Pathogenic	   dn	   Nil	   N/A	   Nil	   1	   M	  




Pathogenic	   inh	   Nil	   N/A	   No	  relevant	  FHx	   0	   M	  
P006	   BMPR1A	  
&	  PTEN	  




Pathogenic	   dn	   Nil	   N/A	   Nil	   0	   F	  
P123	   KIT*	  and	  
PDGFRA*	  
del	   arr[GRCh37]	  
4q12q13.1(53,850,058
Pathogenic	   dn	   nil	   N/A	   nil	   292	   F	  
-­‐65,512,919)x1	  
	  






dn	   nil	   N/A	   Not	  known	  if	  del	  on	  
pat	  or	  mat	  chr.	  	  
100	   M	  




Pathogenic	   dn	   nil	   N/A	   nil	   162	   F	  




Pathogenic	   dn	   nil	   N/A	   nil	   272	   F	  
P127	   MET*	   gain#	  	  	  	   arr[GRCh37]	  
7q21.3q36.3(94,257,5
92-­‐159,124,141)x3	  	  
Pathogenic	   dn	   46,X,der(X)t(X;7)(p21.3;q
21.3).	  arr[GRCh37]	  	  
Xp22.33p21.3(310,953-­‐
28,515,804)x1	  	  	  
	  
pathogenic	   nil	   29	   F	  




Unrelated	   inh	   Nil	   N/A	   No	  relevant	  FHx	   0	   F	  








unknown	   nil	   N/A	   Maximum	  region	  of	  
CNV	  contains	  all	  of	  
exons	  1-­‐6	  and	  part	  





33	   M	  




pathogenic	   dn	   nil	   N/A	   nil	   6	   M	  




pathogenic	   dn	   nil	   N/A	   nil	   30	   M	  






unknown	   nil	   N/A	   nil	   80	   M	  




pathogenic	   dn	   nil	   N/A	   subsequently	  
developed	  RB	  
0	   F	  




pathogenic	   dn	   nil	   N/A	   subsequently	  
developed	  RB	  as	  did	  
MZ	  twin	  
3	   M	  
P139	   SDHA	   del	   arr[GRCh37]	  
5p15.33p14.1(22,149-­‐
pathogenic	   unknown	   nil	   N/A	   nil	   0	   M	  
24,835,505)x1	  
	  




pathogenic	   unknown	   arr[GRCh37]	  
5p15.1p14.1(18,215,614-­‐
26,972,861)x3	  	  
uncertain	  significance	   nil	   3	   F	  




pathogenic	   dn	   nil	   N/A	   nil	   6	   F	  






inh	   nil	   N/A	   nil	   16	   M	  




pathogenic	   dn	   nil	   N/A	   nil	   26	   M	  




pathogenic	   unknown	   nil	   N/A	   nil	   460	   M	  
P121	   SDHA	   del#	   arr[GRCh37]	  
5p15.33p15.31(22,149
-­‐9,700,223)x1	  








pathogenic	   Child	  has	  inherited	  
from	  each	  parent	  (i)	  
unbalanced	  form	  of	  
familial	  
t(5;11)(p15.31;p15.
2)	  (ii)	  familial	  
del(5)(p14.3p15.1)	  
associated	  with	  
learning	  difficulties.	  	  	  
	  
0	   F	  




pathogenic	   dn	   Nil	   N/A	   Nil	   8	   F	  









uncertain	  	  significance	   FHx	  unknown.	  Child	  
has	  inherited	  two	  
dels	  inherited	  from	  
one	  parent	  and	  a	  
balanced	  
translocation	  from	  
the	  other	  parent.	  	  
	  
2	   M	  




pathogenic	   dn	   nil	   N/A	   nil	   74	   M	  




pathogenic	   dn	   nil	   N/A	   del	  on	  pat	  chr	   13	   F	  








pathogenic	   dn	   nil	   N/A	   nil	   97	   M	  






unknown	   nil	   N/A	   nil	   191	   M	  






unknown	   Nil	   N/A	   Nil	   35	   M	  




unrelated	   inh	   Nil	   N/A	   No	  relevant	  FHx	   6	   M	  
P029	   TSC2	   del	   arr[GRCh37]	  
16p13.3(2,097,019-­‐
2,099,039)x1dn	  
pathogenic	   dn	   Nil	   N/A	   TS	  clinically	  
diagnosed	  
subsequently.	  
Deletion	  exons	  1-­‐2	  
TSC2	  on	  minimum	  
co-­‐ordinates.	  
Deletion	  exons	  1-­‐2	  







deletions	  of	  exon	  3	  
and	  5'	  UTR	  to	  exon	  
3	  been	  described	  in	  
TS	  (32-­‐33).	  
7	   M	  
del,	  deletion;	  FHx,	  family	  history;	  dn,	  de	  novo;	  inh,	  inherited;	  *	  oncogene;	  #	  presence	  of	  a	  complex	  chromosomal	  rearrangement;	  F,	  female;	  M,	  male	  
	  
